Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Adamis grants Allergan/Watson US rights to epinephrine PFS; deal ends

Executive Summary

Adamis Pharmaceuticals Corp. granted Watson Laboratories Inc. exclusive rights to market its epinephrine pre-filled syringe (PFS) in the US once it is approved. (Watson was folded into Allergan PLC following a series of mergers, though the company name is still used on some licensing deals.)
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies